// App-Quantinova.ai

OP0155 : ADDITION OF INFLIXIMAB COMPARED WITH ADDITION OF SULFASALAZINE AND HYDROXYCHLOROQUINE TO METHOTREXATE IN EARLY RHEUMATOID ARTHRITIS: 2-YEAR QUALITY OF LIFE RESULTS OF THE RANDOMISED, CONTROLLED SWEFOT TRIAL

Researchers

Presenter

  • J.A. Karlsson

Principal Investigators

  • M. Neovius

  • J.A. Nilsson

  • I.F. Petersson

  • J. Bratt

  • R.F. van Vollenhoven

  • S. Ernestam

  • P. Geborek

Medical Centers

  • Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden

Locations

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Hydroxychloroquine

  • Sulfasalazine

  • Methotrexate

  • Infliximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved